Fuzuloparib combined with abiraterone acetate and prednisone (AA-P) as first-line (1L) treatment for metastatic castration-resistant prostate cancer (mCRPC): Interim results from the FUZUPRO trial.
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Dingwei Ye, Hua Xu, Mariusz Kwiatkowski, Chaochao Liang, Jose Angel Arranz Arija, Shusuan Jiang, Young Seuk Choi, Tie Chong, Chaohong He, Jiwen Cheng, HongQian Guo, Thean Hsiang Tan, Jae Young Joung, Sung Kyu Hong, Ting Sung, Begoña P. Valderrama, Tomáš Büchler, Yiwen Wu, Fan Liang, Wenliang Wang
Institutions: Fudan University Shanghai Cancer Center, First Affiliated Hospital of Anhui Medical University, Hospital General Universitario Gregorio Marañón, Hunan Cancer Hospital, Severance Hospital, Yonsei University Health System, Second Affiliated Hospital of Xi'an Jiaotong University, Henan Cancer Hospital, Guangxi Medical University, First Affiliated Hospital of GuangXi Medical University, Nanjing Drum Tower Hospital, National Cancer Center, Seoul National University Bundang Hospital, First Affiliated Hospital of Nanchang University, Hospital Universitario Virgen del Rocío, Thomayer University Hospital, Jiangsu Hengrui Medicine (China)
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162529526